Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet ...

Opthea (ASX:OPT) has announced that its lead drug candidate sozinibercept has failed to meet primary endpoints in a phase 3 ...

But in 2004, a groundbreaking new treatment called anti-VEGF—including drugs such as Lucentis, Eylea, and Avastin—became available. These drugs work to stop the blood vessels from growing ...

Three drugs — Eylea, Lucentis and Avastin—were compared. All three performed similarly for people with mild DME, while Eylea did better for those who had moderate or worse vision loss. There were 660 ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court.